German funds select Imraldi due to price
Deep initial discounts of up to 40% versus AbbVie’s Humira (adalimumab) original have won Biogen’s Imraldi alternative a nationwide supply contract with Germany’s GWQ group of health insurance funds.
You may also be interested in...
Fresenius Kabi is entering a German adalimumab market in which Amgen, Mylan and Sandoz are already competing against AbbVie’s Humira reference brand. In this environment, Fresenius’ sales expectations are modest.
With quarterly sales up to $36m, Biogen says its Imraldi rival to Humira is the market-leading adalimumab biosimilar in Europe.
The Cincinnati, OH-based firm will pay $8m to recompense Unites States residents who purchased aerosol personal-care products potentially contaminated with benzene over a roughly six-year period.